Catheter ablation of long-standing persistent atrial fibrillation: a lesson from circumferential pulmonary vein isolation.

INTRODUCTION: Circumferential pulmonary vein isolation (CPVI) is associated with a high success rate in patients with paroxysmal and persistent atrial fibrillation (AF). However, in patients with long-standing persistent AF, the ideal ablation strategy still remains a matter of debate. METHODS AND RESULTS: Two-hundred and five patients underwent catheter ablation for long-standing persistent AF defined as continuous AF of more than 1-year duration. In a first step, all patients underwent CPVI. If direct-current cardioversion failed following CPVI, ablation of complex fractionated atrial electrograms (CFAEs) was performed. The goal was conversion into sinus rhythm (SR) or, alternatively, atrial tachycardia (AT) with subsequent ablation. A total of 340 procedures were performed. CPVI alone was performed during 165 procedures in 124 of 205 (60.5%) patients. In the remaining 81 patients, additional CFAE ablation was performed in 45, left linear lesions for recurrent ATs in 44 and SVC isolation in 15 patients, respectively, resulting in inadvertent left atrial appendage isolation in 9 (4.4%) patients. After the initial ablation procedure, 67 of 199 patients remained in SR during a mean follow-up of 19 ± 11 months. Six patients were lost to follow-up. After a mean of 1.7 ± 0.8 procedures, 135 of 199 patients (67.8%) remained in SR. Eighty-six patients (43.2%) remained in SR following CPVI performed as the sole ablative strategy. CONCLUSIONS: CPVI alone is sufficient to restore SR in 43.2% of patients with long-standing persistent AF. Multiple procedures and additional ablation strategies with a significant risk of inadvertent left atrial appendage isolation are often required to maintain stable SR.

Long-term clinical outcome following pulmonary vein isolation with high-intensity focused ultrasound balloon catheters in patients with paroxysmal atrial fibrillation.

AIMS: High-intensity focused ultrasound (HIFU) applied via a balloon catheter is a novel technology for pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (PAF). The long-term success rate is unknown. METHODS AND RESULTS: Thirty-two patients (22 male, age 60 +/- 9 years) with a long history [5 (4;9) years] of drug refractory [3 +/- 1 anti-arrhythmic drugs (AADs)], symptomatic PAF were included into the analysis. Pulmonary vein isolation was performed using the first- and second-generation HIFU balloon catheters (ProRhythm, Ronkonkoma, NY, USA). Follow-up (F/U) included regular telephonic interviews, trans-telephonic Holter ECG, and event recording. Recurrence was defined as a documented or symptomatic AF episode >30 s without a blanking period. In total 101/116 targeted PVs (87%) were acutely isolated exclusively using HIFU. During a median F/U of 1400 (930;1568) days, 18 patients (56%) were free of AF without AAD after a single HIFU procedure. In nine patients with AF recurrence, 20 PVs exhibited electrical reconduction and re-isolation was performed using irrigated radiofrequency current (RFC) ablation. CONCLUSION: Patients treated with the first- and second-generation HIFU balloon catheters due to symptomatic PAF show long-term success rates similar to RFC-based PVI procedures. The major determinant of AF recurrence after HIFU treatment seems to be reconduction of previously isolated PVs. However, the favourable effectiveness is offset by the severe complications reported following HIFU treatment. This led to a halt of its clinical use.

Esophageal temperature change and esophageal thermal lesions after pulmonary vein isolation using the novel endoscopic ablation system.

BACKGROUND: Pulmonary vein isolation (PVI) is an established treatment option for paroxysmal atrial fibrillation. Recently, a novel endoscopic ablation system (EAS) was introduced. The incidence and severity of ablation-induced esophageal thermal lesions (ETLs) are unknown. OBJECTIVE: The purpose of this study was to investigate the incidence and severity of ablation-induced ETLs. METHODS: This prospective analysis compared two groups: group A underwent EAS-based PVI, and group B received PVI using radio frequency current (RFC). If esophageal temperature measured via an endoluminal temperature probe exceeded 38.5°C, energy application was stopped immediately. Endoscopy was performed 2 days postablation. RESULTS: Forty patients (20 female, mean age 56 ± 10 years) were treated with the EAS system (group A). In 20 patients (seven female, mean age 63 ± 9 years) RFC-based PVI was performed (group B). Esophageal endoscopy was performed 2.1 ± 0.8 (group A) and 2.8 ± 1.2 days postablation (group B), respectively. In 7/40 patients (18%) in group A, thermal lesions (four thermal ulcerations, three minimal thermal lesions) were detected. In group B, 3/20 patients (15%) displayed thermal lesions (three minimal thermal lesions). All thermal lesions resolved upon repeat endoscopy performed 8 ± 6 (group A) and 5 ± 1 days (group B) after initial endoscopy. CONCLUSION: In the EAS group, ETLs were found in 18% of patients, as compared with in 15% in the RFC group. In patients with ETLs, ulcerations were found in 57% in the EAS group, as compared with 0% in the RFC group. This may indicate that the quality of thermal lesions is more severe in the EAS group. Further investigation is required.

One-year clinical outcome after pulmonary vein isolation using the novel endoscopic ablation system in patients with paroxysmal atrial fibrillation.

BACKGROUND: Pulmonary vein isolation (PVI) is an established treatment option for atrial fibrillation (AF). Recently the novel endoscopic ablation system (EAS) was introduced and proved potential for successful acute PVI. OBJECTIVE: This study sought to investigate the 1-year follow-up results after EAS-based PVI. METHODS: A total of 40 patients (20 female, age 57 ± 9 years) with a long history (5 ± 4 years) of drug-refractory (2 ± 1 antiarrhythmic drugs) paroxysmal AF were included into our analysis. PVI was performed using exclusively the novel EAS. Follow-up included regular telephonic interviews, Holter electrocardiographic (ECG) and transtelephonic ECG recordings. A symptomatic or documented AF episode >60 seconds after a blanking period of 3 months was defined as recurrence. RESULTS: A total of 155 PVs were targeted; 153 of 155 (99%) PVs were isolated successfully using exclusively the novel EAS. During a median follow-up of 402 (331 to 478; quartile 1 to quartile 3) days, 24 of 40 patients (60%) remained free of any symptomatic or documented AF episode without antiarrhythmic drugs after a single procedure. Seven patients suffering from AF recurrence underwent radiofrequency current-based Re-PVI 203 ± 102 days after the index EAS-based procedure. Left atrium to pulmonary vein reconduction was found in 17 of 25 initially isolated PVs. No PV stenosis was detected based on magnetic resonance imaging 3 months postablation. CONCLUSION: Patients after EAS-based PVI due to paroxysmal AF demonstrate 1-year single-procedure success rates similar to those of other ablation techniques and ablation energies. The major determinant for AF recurrence after EAS treatment seems to be reconnection of previously isolated PVs. More patients and longer follow-up periods are mandatory before final conclusions can be drawn regarding the efficacy and safety of the EAS.